Anders Hammerich Riis

Anders Hammerich Riis

Auto-generated profile, based on publicly available information

Anders Hammerich Riis

Department of Clinical Epidemiology, Aarhus University Hospital, Aarhus, Denmark

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2008 in Diabetes Care
Verified
Journal Article
Open access
JKJette B. Kornum
Jette B. Kornum
RTReimar W. Thomsen
Reimar W. Thomsen
ARAnders Riis
Anders Riis
HLHans-Henrik Lervang
Hans-Henrik Lervang
HSHenrik C. Schønheyder
Henrik C. Schønheyder
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
OBJECTIVE—To examine whether diabetes is a risk factor for hospitalization with pneumonia and to assess the impact of A1C level on such risk. RESEARCH DESIGN AND METHODS—In this population-based, case-control study we identified patients with a first-time pneumonia-related hospitalization between 1997 and 2005, using health care databases in northern Denmark. For each case, 10 sex- and age-matched population control subjects were selected from Denmark's Civil Registration System. We used conditional logistic regression to compute relative risk (RR) for pneumonia-related hospitalization among subjects with and without diabetes, controlling for potential confounding factors. RESULTS—The study included 34,239 patients with a pneumonia-related hospitalization and 342,390 population control subjects. The adjusted RR for pneumonia-related hospitalization among subjects with diabetes was 1.26 (95% CI 1.21–1.31) compared with nondiabetic individuals. The adjusted RR was 4.43 (3.40–5.77) for subjects with type 1 diabetes and 1.23 (1.19–1.28) for subjects with type 2 diabetes. Diabetes duration ≥10 years increased the risk of a pneumonia-related hospitalization (1.37 [1.28–1.47]). Compared with subjects without diabetes, the adjusted RR was 1.22 (1.14–1.30) for diabetic subjects whose A1C level was <7% and 1.60 (1.44–1.76) for diabetic subjects whose A1C level was ≥9%. CONCLUSIONS—Type 1 and type 2 diabetes are risk factors for a pneumonia-related hospitalization. Poor long-term glycemic control among patients with diabetes clearly increases the risk of hospitalization with pneumonia.

26 May 2009 in PLOS Medicine
Verified
Journal Article
Open access
PDF file
Zitta F B Barrella HarboeZitta F B Barrella Harboe
Zitta F B Barrella Harboe
RTReimar W Thomsen
Reimar W Thomsen
ARAnders Riis
Anders Riis
PVPalle Valentiner-Branth
Palle Valentiner-Branth
JCJens Jørgen Christensen
Jens Jørgen Christensen
TBThomas Benfield
Thomas Benfield
Pneumococcal disease is a leading cause of morbidity and mortality worldwide. The aim of this study was to investigate the association between specific pneumococcal serotypes and mortality from invasive pneumococcal disease (IPD). In a nationwide population-based cohort study of IPD in Denmark during 1977–2007, 30-d mortality associated with pneumococcal serotypes was examined by multivariate logistic regression analysis after controlling for potential confounders. A total of 18,858 IPD patients were included. Overall 30-d mortality was 18%, and 3% in children younger than age 5 y. Age, male sex, meningitis, high comorbidity level, alcoholism, and early decade of diagnosis were significantly associated with mortality. Among individuals aged 5 y and older, serotypes 31, 11A, 35F, 17F, 3, 16F, 19F, 15B, and 10A were associated with highly increased mortality as compared with serotype 1 (all: adjusted odds ratio ≥3, p<0.001). In children younger than 5 y, associations between serotypes and mortality were different than in adults but statistical precision was limited because of low overall childhood-related mortality. Specific pneumococcal serotypes strongly and independently affect IPD associated mortality.

14 October 2009 in Human Reproduction
Verified
Journal Article
Open access
PDF file
Lauren WiseLauren Wise
Lauren Wise
KRKenneth J. Rothman
Kenneth J. Rothman
EMEllen M. Mikkelsen
Ellen M. Mikkelsen
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
ARAnders Riis
Anders Riis
EHElizabeth E. Hatch
Elizabeth E. Hatch
Recent studies have shown that both female and male obesity may delay time-to-pregnancy (TTP). Little is known about central adiposity or weight gain and fecundability in women. We examined the association between anthropometric factors and TTP among 1651 Danish women participating in an internet-based prospective cohort study of pregnancy planners (2007–2008). We categorized body mass index (BMI = kg/m2) as underweight (<20), normal weight (20–24), overweight (25–29), obese (30–34) and very obese (≥35). We used discrete-time Cox regression to estimate fecundability ratios (FRs) and 95% confidence intervals (CI), controlling for potential confounders. We found longer TTPs for overweight (FR = 0.83, 95% CI = 0.70–1.00), obese (FR = 0.75, 95% CI = 0.58–0.97), and very obese (FR = 0.61, 95% CI = 0.42–0.88) women, compared with normal weight women. After further control for waist circumference, FRs for overweight, obese, and very obese women were 0.72 (95% CI = 0.58–0.90), 0.60 (95% CI = 0.42–0.85) and 0.48 (95% CI = 0.31–0.74), respectively. Underweight was associated with reduced fecundability among nulliparous women (FR = 0.82, 95% CI = 0.63–1.06) and increased fecundability among parous women (FR = 1.61, 95% CI = 1.08–2.39). Male BMI was not materially associated with TTP after control for female BMI. Compared with women who maintained a stable weight since age 17 (−5 to 4 kg), women who gained ≥15 kg had longer TTPs (FR = 0.72, 95% CI = 0.59–0.88) after adjustment for BMI at age 17. Associations of waist circumference and waist-to-hip ratio with TTP depended on adjustment for female BMI: null associations were observed before adjustment for BMI and weakly positive associations were observed after adjustment for BMI. Our results confirm previous studies showing reduced fertility in overweight and obese women. The association between underweight and fecundability varied by parity.

1 March 2010 in American Journal of Respiratory and Critical Care Medicine
Verified
Journal Article
Closed access
CAClaire Andréjak
Claire Andréjak
VTVibeke Ø. Thomsen
Vibeke Ø. Thomsen
IJIsik Somuncu Johansen
Isik Somuncu Johansen
ARAnders Riis
Anders Riis
TBThomas Benfield
Thomas Benfield
RTReimar W. Thomsen
Reimar W. Thomsen
Rationale: Few population-based data are available regarding nontuberculous mycobacteria (NTM) pulmonary disease epidemiology and prognosis. Objectives: To examine NTM pulmonary colonization incidence, disease incidence, and prognostic factors. Methods: All adults in Denmark with at least one NTM-positive pulmonary specimen during 1997 to 2008 were identified using national medical databases and were categorized as having possible or definite NTM disease or colonization. Measurements and Main Results: We calculated annual age-standardized NTM incidence rates and adjusted hazard ratios (HR) of death associated with patient age, sex, comorbidity, NTM species, and NTM disease status. Of 1,282 adults with 2,666 NTM-positive pulmonary specimens, 335 (26%) had definite NTM disease, 238 (19%) possible disease, and 709 (55%) colonization only. NTM incidence rates decreased until 2002, followed by an increase from 2003 to 2008 (mean annual rate per 100,000 person-years: NTM colonization, 1.36; NTM disease, 1.08). Five-year mortality after definite NTM disease was 40.1%. After controlling for potential confounders, 5-year mortality for definite NTM disease was slightly higher than for NTM colonization (adjusted hazard ratio [HR], 1.15; 95% confidence interval [CI], 0.90–1.51). Mycobacterium xenopi was associated with worse prognosis (adjusted HR, 1.51; 95% CI, 0.99–2.33) than the reference Mycobacterium avium complex. High comorbidity level (HR, 2.97), age greater than or equal to 65 years (HR, 9.17), and male sex (female sex HR, 0.73) were predictors of death. Conclusions: NTM disease incidence has remained unchanged in Denmark over the past 12 years. Patients with NTM colonization and disease have similarly poor prognosis. Negative prognostic factors include high levels of comorbidity, advanced age, male sex, and M. xenopi.

1 September 2007 in Diabetes Care
Verified
Journal Article
Open access
PDF file
JKJette B. Kornum
Jette B. Kornum
RTReimar W. Thomsen
Reimar W. Thomsen
ARAnders Riis
Anders Riis
HLHans-Henrik Lervang
Hans-Henrik Lervang
HSHenrik C. Schønheyder
Henrik C. Schønheyder
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
OBJECTIVE—We sought to examine whether type 2 diabetes increases risk of death and complications following pneumonia and to assess the prognostic value of admission hyperglycemia.

1 October 2011 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
PDF file
SLStanley Lemeshow
Stanley Lemeshow
Henrik Toft SørensenHenrik Toft Sørensen
Henrik Toft Sørensen
GPGary Phillips
Gary Phillips
EYEric V. Yang
Eric V. Yang
SASussie Antonsen
Sussie Antonsen
RGRonald Glaser
Ronald Glaser
Background: To study whether use of β-blockers increases survival in patients with malignant melanoma because experimental data suggest that catecholamine hormones may be involved in stimulating the aggressiveness of malignant melanoma. Methods: A total of 4,179 patients diagnosed with malignant melanoma in Denmark with a median follow-up of 4.9 years and identified in the Danish Cancer Registry participated. Data on β-blocker use, comorbidity, and survival were obtained from medical and administrative databases. Cox proportional hazards models were used to estimate HRs for all-cause mortality with 95% CIs with adjustment for prognostic factors. Results: A total of 372 (8.9%) patients with malignant melanoma were treated with β-blockers within 90 days of melanoma diagnosis. The median β-blocker duration for exposure within 90 days of melanoma diagnosis, more than 90 days, and no prior exposure was 7.6, 1.4, and 0 years, respectively. The patients receiving β-blockers were older, had more comorbidities, and more cardiovascular and psychotropic drug user than the patients receiving no β-blockers prior to melanoma diagnosis. After adjustment for age and comorbidity index, the HR for melanoma death was 0.87 (95% CI: 0.64–1.20) and for all-cause mortality was 0.81 (95% CI: 0.67–0.97). Conclusion: Increased survival time of patients with melanoma receiving β-blockers suggests that this class of drugs may hold promise in treatment strategy for these patients. Impact: The observations described here suggest that catecholamines may retard melanoma progression and that β-blockers may have unrecognized potential as a therapeutic intervention for melanoma. Cancer Epidemiol Biomarkers Prev; 20(10); 2273–9. ©2011 AACR.